Biotech and Pharmaceuticals Pharmaceuticals

More

  • The SEC has questioned Valeant's practice of stripping away acquisition-related expenses from its "non-GAAP" or adjusted metrics, given that the drugmaker had been fueling growth through frenzied deal making. In multiple letters, the SEC said Valeant's management is in possession of all the facts and urged for adequate and accurate financial disclosures.

  • The SEC has questioned Valeant's practice of stripping away acquisition-related expenses from its "non-GAAP" or adjusted metrics, given that the drugmaker had been fueling growth through frenzied deal making. In multiple letters, the SEC said Valeant's management is in possession of all the facts, and urged for adequate and accurate financial disclosures.

  • May 24- Shares of Herbalife Ltd jumped as much as 8.5 percent amid conflicting reports on whether the company had reached an agreement in principle with the U.S. Federal Trade Commission to settle a probe into whether it runs a pyramid scheme. The nutritional supplements maker's stock soared after the New York Post said a settlement was imminent but came off its...

  • Health care costs

    Although cost increases have slowed, prescription drug spending has helped to boost health costs for an average family to a new milestone.

  • LLY CEO: One issues with TPP

    Eli Lilly CEO John Lechleiter talks about the impact of the dollar, taxes, and the problem he sees with the Trans-Pacific Partnership agreement. Also Lechleiter provides an update on Alzheimer's treatment.

  • LLY CEO: Fundamentals never stronger

    Eli Lilly CEO John Lechleiter discusses cycles in the industry and products coming out of the company's labs. We're very optimistic about our future, says Lechleiter. We have a chance to introduce 20 new products in the next ten years and are off to a good running start.

  • The repercussions of the Bayer-Monsanto deal

    Neil Dwane, global strategist at Allianz Global Investors, says many Bayer investors will view the deal negatively as they won't own Monsanto.

  • The value of M&A to pharma

    John Rountree, managing partner at Novasecta, talks about whether or not the Bayer-Monsanto merger would create more or less innovation and value.

  • Bayer says it has offered $122 per share for Monsanto in an all-cash deal that values the U.S. company at $62 billion.

  • FRANKFURT, Germany— Bayer wants to buy Monsanto for $62 billion, hooking up the German chemical and drug company with the St. Louis- based producer of seeds and weed-killers. A: Bayer is offering to acquire Monsanto, which makes seeds for fruits, vegetables, corn, soybeans and cotton, as well as weed-killer Roundup. That compares with a closing price Friday of $101.52...

  • Bayer offers $122 per share for Monsanto

    The pharmaceutical company Bayer has announced plans to acquire American biotech company Monsanto, making an all cash offer of $122 per share.

  • SHANGHAI, May 23- Promises of higher salaries and greater freedom at work are luring officials from China's high-profile drugs watchdog to the companies they had regulated, a blow just as the country looks to tighten oversight and drive innovation. China wants to crack down on substandard drugs and healthcare as it seeks to produce more of the drugs consumed in...

  • Sarepta awaits drug approval

    CNBC's Meg Tirrell talks about whether the FDA will approve Sarepta's Muscular Dystrophy drug and what could happen to the company's stock. The "FMHR" traders debate the trade.

  • SHANGHAI/ LONDON, May 20- Chinese health authorities announced price cuts of up to two-thirds for three drugs on Friday in the latest move to reduce the cost of healthcare for patients in the world's second-biggest economy. Icotinib, another lung cancer drug made by China's Betta Pharmaceuticals, will come down to 5,500 from 12,000 yuan a month.

  • May 19- Beleaguered Canadian drugmaker Valeant Pharmaceuticals International Inc said it received a notice of default from bondholders for the delay in filing its first-quarter report. Last week, Valeant had said it expected to file the report with U.S. and Canadian regulators on or before June 10, ahead of a July 31 deadline. The Laval, Quebec- based company's...

  • May 19- Beleagured Canadian drugmaker Valeant Pharmaceuticals International Inc said it received a notice of default from bondholders for the delay in filing its quarterly report. The Laval, Quebec- based company said it can avert default by filing the report by July 18. Last week, the company said it expected to file its first-quarter report with U.S. and...

  • Elizabeth Holmes, founder and CEO of Theranos.

    Blood-testing startup Theranos posted a job opening Thursday looking for an executive assistant to CEO Elizabeth Holmes.

  • NEW YORK, May 19- Late in July 2012, Phil Mickelson, one of the world's most famous golfers, received a phone call from a well-known professional sports gambler, William "Billy" Walters. "Simply put, Mickelson made money that wasn't his to make," Andrew Ceresney, the SEC's enforcement chief, said at a news conference in New York on Thursday. Mickelson, 45, was named as a "...

  • *CEO stands by peak annual sales forecast of $5 billion. ZURICH, May 19- Novartis's heart failure drug Entresto will be subjected to a battery of new trials as the Swiss drugmaker seeks to boost the medicine after a disappointing introduction. Entresto's stuttering launch was overseen by Novartis pharma chief David Epstein, who quit this week.

  • Illustration of the Zika virus.

    IBM's World Community Grid links volunteers' personal computers and mobile devices to form a supercomputer for disease research.